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A human homolog of the C. elegans polarity determinant Par-6
links Rac and Cdc42 to PKCz signaling and cell transformation
Rong-Guo Qiu*, Arie Abo† and G. Steven Martin*
Background: Rac and Cdc42 are members of the Rho family of small GTPases.
They modulate cell growth and polarity, and contribute to oncogenic
transformation by Ras. The molecular mechanisms underlying these functions
remain elusive, however.
Results: We have identified a novel effector of Rac and Cdc42, hPar-6,
which is the human homolog of a cell-polarity determinant in Caenorhabditis
elegans. hPar-6 contains a PDZ domain and a Cdc42/Rac interactive binding
(CRIB) motif, and interacts with Rac1 and Cdc42 in a GTP-dependent
manner. hPar-6 also binds directly to an atypical protein kinase C isoform,
PKCz, and forms a stable ternary complex with Rac1 or Cdc42 and PKCz .
This association results in stimulation of PKC z kinase activity. Moreover,
hPar-6 potentiates cell transformation by Rac1/Cdc42 and its interaction
with Rac1/Cdc42 is essential for this effect. Cell transformation by
hPar-6 involves a PKC z -dependent pathway distinct from the pathway
mediated by Raf.
Conclusions: These findings indicate that Rac/Cdc42 can regulate cell growth
through Par-6 and PKCz, and suggest that deregulation of cell-polarity
signaling can lead to cell transformation.
Background 
Rac and Cdc42 are members of the Rho GTPase family,
which in turn constitutes a subfamily of the Ras superfam-
ily [1]. Like all other Ras-related proteins, Rac and Cdc42
act as molecular switches, cycling between the active
GTP-bound and the inactive GDP-bound states [2]. In the
GTP-bound form, they interact with downstream effectors
to elicit biological responses, including actin cytoskeletal
organization, membrane trafficking and cell adhesion [2–4]. 
An important theme that has emerged during the past
several years is that Rac and Cdc42 also have essential
roles in growth control and contribute to oncogenic
transformation [5]. They stimulate DNA synthesis,
promote cell-cycle progression and mediate survival sig-
naling [6,7]. Several observations indicate that deregula-
tion of Rac1 and Cdc42 signaling can lead to cell
transformation. First, overexpression of activated
mutants of Rac1 or Cdc42 results in growth transforma-
tion in fibroblasts [8–11]. In addition, activated Rac1 and
Cdc42 have been reported to synergize with activated
Raf in focus assays [8,10,12]. Moreover, Rac and Cdc42
are required for cell transformation induced by oncogenic
Ras in fibroblasts [8–10] and epithelial cells [13]. Despite
many efforts to identify the downstream targets responsi-
ble for Rac- and Cdc42-mediated growth control [5,14],
the pathway by which Rac1 and Cdc42 transform cells
remains unknown. 
It is becoming increasingly evident that Rac and Cdc42
are also important regulators of cell polarity in many dif-
ferent eukaryotic cells [2,15–19]. Two other groups of pro-
teins have also been implicated in the determination of
cell polarity. In Caenorhabditis elegans six par (partitioning
defective; par-1 to par-6) genes required for asymmetric
segregation of cell-fate determinants have been identified
[20] and homologs of some of these par genes have been
isolated in other metazoans [21–24]. Recent studies have
also suggested a role for the atypical PKCs (PKCz , PKC l/i
of mammals and PKC-3 of C. elegans) in cell polarity
[22,24]. In addition to its role in cell polarity, PKCz also
has a critical role in many processes involved in mitogenic
signaling and growth control [25–28]. 
Here we report the cloning and characterization of a human
homolog of Par-6 (hPar-6) and present evidence that hPar-6
is a novel effector of Rac1 and Cdc42. We show that hPar-6
physically links Rac1 or Cdc42 to PKC z and mediates
PKCz -dependent transformation by Rac1 and Cdc42. 
Results 
Two-hybrid screen identifies hPar-6 as a putative effector
of Rac1 and Cdc42
To isolate novel effectors of Cdc42, we performed a yeast
two-hybrid screen [29] using activated Cdc42(Q61L) as
bait. Of seven positive clones obtained from a human
cDNA library prepared from HeLa cells, clone 2HP-4
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interacted strongly with constitutively active Rac1(Q61L)
and Cdc42(Q61L), but not with their dominant-negative
counterparts, Rac1(T17N) and Cdc42(T17N), nor with
activated RhoA or Ras or the unrelated protein lamin
(data not shown; see Supplementary material), suggesting
that it is a putative effector of Rac1 and Cdc42. The inter-
action of 2HP-4 with Cdc42 appears stronger than the
interaction between p21-activated kinase, PAK [30], and
Cdc42 (see Supplementary material). Sequence analysis
revealed that 2HP-4 encodes part of a protein that con-
tains a PDZ domain and a CRIB motif (Figure 1a,c). This
protein is a human homolog of C. elegans Par-6, the
sequence of which was published during the course of
this study [22]. We therefore named this novel protein
hPar-6. A partial cDNA with identical sequence to 2HP-4
was recently isolated in an unrelated study as a protein
(TIP40) that interacts with Tax, the transactivator of
human T-cell leukemia virus [31]. 
To determine the tissue distributions of hPar-6 and the
size of the full-length cDNA, a multiple-tissue northern
blot was analyzed using the 2HP-4 cDNA insert as a
probe. The gene is ubiquitously, but differentially, tran-
scribed as a 1.3 kb mRNA in all tissues examined, with
highest levels of expression in brain, heart, skeletal
muscle, kidney and liver (Figure 1b). 
A cDNA clone of hPar-6 was then obtained from the
EST (expressed sequence tag) database and its sequence
re-analyzed. It contains a cDNA insert of 1246 bp (data
not shown). Three lines of evidence indicate that this
EST clone encodes full-length hPar-6. First, the insert
size corresponds to that of the mRNA (Figure 1b).
Second, the clone contains an open reading frame of 345
amino acids (Figure 1a,c), only one amino acid less than
that of its mouse counterpart which has been deposited
in the database [22]. Finally, the nucleotides CCGCC
immediately upstream of the start codon form a perfect
consensus Kozak sequence. Homologs of Par-6 from
Drosophila and Xenopus were also found in the EST data-
base or identified [22,32], indicating that Par-6 has been
conserved in evolution. In addition to a high degree of
sequence similarity within the PDZ domain, Par-6 pro-
teins show a high degree of sequence similarity in the
CRIB-like motif (Figure 1c). Nevertheless, sequence
comparison indicates that the CRIB motif of hPar-6 does
not retain some of the most conserved residues (for
example HXXH, where X is any amino acid) that are
present in other CRIB-motif-containing effectors [5],
suggesting that these residues are not required for inter-
action between hPar-6 and Rac1/Cdc42. The hPar-6
cDNA sequence has been deposited in GenBank, acces-
sion number AF265565.
We have also identified in the database the partial
sequence of a human protein, CAB44747, which shows
about 46% sequence identity to hPar-6 (Figure 1c). In
addition, we have found other human EST clones (for
example IMAGE clones 1540865, 1474395 and 2531285)
that share sequence homology with hPar-6. These find-
ings indicate the existence of a family of hPar-6 proteins.
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Figure 1
Par-6 is conserved in evolution. (a) Full-length hPar-6 and the 2HP-4
clone (hPar-2HP) are shown schematically. CRIB, Cdc42/Rac
interactive binding motif; PDZ, PDZ domain. The residue numbers
indicate the approximate limits of each domain. (b) Tissue distribution
of hPar-6 mRNA. The size markers (in kb) are shown at the left.
The blot was also probed with actin cDNA as an RNA loading control
(bottom panel). (c) Sequence alignments of Par-6 from C. elegans
(cPar-6), Drosophila (dPar-6), Xenopus (xPar-6), mouse (mPar-6) and
human (hPar-6), and clone CAB44747. The sequences corresponding
to the CRIB motif in hPar-6 are boxed and those corresponding to the
PDZ domain are underlined.
hPar-6 interacts with activated Rac1 and Cdc42 in vitro and
in vivo 
To obtain direct evidence that hPar-6 is an effector of
Rac1 and Cdc42, we assayed their interaction both in vitro
and in vivo (see Materials and methods). Full-length
hPar-6 binds specifically to glutathione-S-transferase
(GST) fusions of wild-type Rac1 (GST–Rac) or Cdc42
(GST–Cdc42) when these proteins are pre-loaded with
GTPg S (a non-hydrolyzable analog of GTP), but not when
pre-loaded with GDP (Figure 2a). Conversely,
GST–hPar-6 or GST–hPar-2HP (corresponding to 2HP-4)
binds activated mutants of Rac1 and Cdc42 (provided as
either in vitro translated proteins, transfected cell lysates or
purified proteins), but does not bind their dominant-nega-
tive versions, nor other control proteins such as activated
RhoA, activated Ras or E-cadherin (Figure 2b,c; see Sup-
plementary materials). Thus, the interaction between
hPar-6 and Rac1/Cdc42 is direct, specific and GTP depen-
dent. Moreover, Rac1(Q61L) and Cdc42(Q61L) are co-
immunoprecipitated with hPar-6 or hPar-2HP from cells
overexpressing both proteins, indicating that the interac-
tion can occur in vivo (Figure 2d,e). Deletion of the CRIB
motif of hPar-6 abolishes its interaction with Rac1/Cdc42
both in vitro and in vivo (Figure 2a,e), suggesting that
binding of hPar-6 to Rac1/Cdc42 is mediated by this motif.
Taken together, these data indicate that hPar-6 interacts
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Figure 2
hPar-6 shows GTP-dependent interaction with
Rac1/Cdc42 in vitro and in vivo. (a) In vitro
interaction assays using GST–Rac1 and
Cdc42 loaded with either GTPg S or GDP, and
COS cell lysates containing Myc-tagged
versions of the two-hybrid protein (hPar-2HP),
full-length hPar-6, or the CRIB deletion mutant
(hPar-D CRIB) of hPar-6 (see Figure 3c for
descriptions of mutants). The precipitates
were analyzed by western blotting with 9E10
anti-Myc monoclonal antibody (upper panels).
The lower panel shows the levels of hPar-2HP,
hPar-6 and hPar-D CRIB in 16% of the cell
lysates used in the assay. (b) In vitro
interaction assays showing direct interaction
of hPar-2HP with Rac1 and Cdc42. Purified
recombinant Rac1(Q61L), Cdc42(Q61L) or
Ras(G12V) (2 m g each) were incubated with
either GST–hPar-2HP (GST–2HP) or GST
control. Precipitated proteins were detected
by western blotting with a combination of
antibodies against Rac, Cdc42 and Ras. The
upper panel shows the results of the
precipitations. The lower panel shows a
Coomassie blue stain of 2 m g purified Rac1,
Cdc42 and Ras. (c) In vitro interaction assays
showing interaction of full-length hPar-6 with
Rac1 and Cdc42. COS cell lysates containing
the proteins as indicated above each lane
were incubated with either GST–hPar-6 or
GST control. Precipitated proteins were
detected by western blotting with F-7 anti-HA
antibody. (d) Co-immunoprecipitation (IP) of
hPar-6 with Rac1/Cdc42. An expression
construct encoding Myc-tagged hPar-2HP
was co-transfected into COS cells with either
empty vector or expression plasmids encoding
the proteins as indicated above each lane.
Myc–hPar-2HP was immunoprecipitated from
the cell lysates with 9E10 anti-Myc antibody,
and the precipitates were analyzed by western
blotting (WB) with a combination of F-7 anti-
HA and anti-Ras antibodies (upper panel).
Similar blots were also probed separately with
F-7 or anti-Ras with identical results (data not
shown). The lower panel shows the levels of
HA-tagged Rac1/Cdc42/RhoA mutants, and
Ras mutants in 16% of the input cell lysates
used in the assay. Levels of the proteins in the
cell lysates were similar in (c) and (d).
(e) CRIB-dependent interaction in vivo.
Constructs encoding HA-tagged Rac1(Q61L)
or Cdc42(Q61L) were co-transfected into
COS cells with either empty vector, or a
construct encoding Myc-tagged hPar-2HP,
hPar-6 or hPar-D CRIB. Myc-tagged proteins
were immunoprecipitated from the cell lysates
with 9E10 anti-Myc, and the precipitates were
analyzed by western blotting with F-7 anti-HA
(upper panel). The lower panel shows in
duplicate the levels of hPar-2HP, hPar-6 and
hPar-D CRIB in 20% of the input cell lysates in
the assay. 
with Rac1/Cdc42 both in vitro and in vivo, and further
confirm that hPar-6 is an effector of Rac1 and Cdc42. 
Full-length hPar-6 interacts with Rac1/Cdc42 less effi-
ciently than does hPar-2HP (Figure 2a,e), suggesting that
in the full-length protein the CRIB motif is less accessible
or has a lower affinity for Rac1/Cdc42. One possible inter-
pretation is that an intramolecular interaction may occur
between the amino and carboxyl termini of hPar-6,
masking the CRIB domain and preventing its interaction
with Rac1 and Cdc42. Alternatively, some proteins that
bind to the amino- and/or carboxy-terminal regions may
influence the interaction.
hPar-6 links Rac1/Cdc42 to PKCz
It was demonstrated recently that in the early embryo of
C. elegans, Par-6 and an atypical PKC homolog, PKC-3,
have an overlapping distribution and that stable localiza-
tion of these two proteins at the cell periphery is depen-
dent on each other’s function [22]. This observation
suggests that Par-6 and PKC-3 may form a complex. To
address the possibility that hPar-6 might associate with a
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Figure 3
hPar-6 interacts specifically with atypical
PKC. (a) In vitro interaction of hPar-6 with
PKC z but not PKC a . Equal amounts of
35S-labeled PKC z and PKC a made by TNT
(see Materials and methods) were incubated
with either GST–hPar-6 or GST control. The
precipitates were detected by
autoradiography (upper panel). The lower
panel shows 20% of the input TNT PKC
signals. (b) Direct interaction of hPar-6 with
PKC z but not with PKC d . Assays were
performed as in (a) except that 3 m g of
purified recombinant PKC z or PKC d
(Calbiochem) were used instead of in vitro
translated proteins. The precipitates were
analyzed by western blotting with anti-PKCz
and anti-PKC d antibodies (Santa Cruz
Biotechnology) (upper panel). The lower
panel shows the Coomassie blue stain of
3 m g of the purified PKC. (c) Schematic
representation of different mutants of hPar-6
and summary of their interactions with PKCz .
+++, Strong interaction; +/–, very little
interaction; –, no detectable interaction. Data
documenting interaction between hPar-2HP
and PKC z are not shown. (d) Co-
immunoprecipitation of hPar-6 with PKCz .
COS cell lysates containing Myc-tagged
vector, hPar-6 or hPar- D CRIB with (left three
lanes) or without (right three lanes) co-
transfected PKC z were immunoprecipitated
(IP) with 9E10 anti-Myc, and the
immunoprecipitates were analyzed by
western blotting (WB) with anti-PKCz . The
expression level of each hPar-6 construct
was detected by western blotting with 9E10
(data not shown). Equivalent amounts of
hPar-6 or hPar- D CRIB were then used in the
experiment. (e) Mapping the PKC z
interaction region of hPar-6. Constructs
expressing Myc-tagged hPar-6 and different
deletion mutants of hPar-6 (see (c)) were co-
transfected into COS cells with a construct
expressing either PKC z or kinase-dead (KD)
PKC z ( PKC z (K281W)). The cell lysates were
then analyzed by immunoprecipitation with
9E10 anti-Myc followed by western blotting
with anti-PKC z ( upper panel). The expression
level of each hPar-6 mutant was detected by
western blotting with 9E10 (lower panel).
Equivalent amounts of hPar-6 or its mutants
were then used in the experiment.
(f) Interaction of overexpressed hPar-6 with
endogenous PKC z . Constructs encoding
Myc-tagged hPar-6 or different mutants of
hPar-6 were transfected into COS cells and the
lysates were analyzed by immunoprecipitation
with 9E10 anti-Myc followed by western
blotting with anti-PKC z . Expression of Myc-
tagged hPar-6 mutants was confirmed by
western blotting with 9E10 antibody (data
not shown). Equivalent amounts of hPar-6 or
its mutants were then used in the experiment.
(g) Complex formation between endogenous
Par-6 and PKC z . Endogenous PKC z in cell
lysates containing 1.5 mg (NIH-3T3 and
IEC18) or 1 mg (SW480) of total protein
were immunoprecipitated with anti-PKCz or
control anti-Myc antibody. The precipitates
were then analyzed with anti-hPar-6
antiserum for co-precipitated endogenous
Par-6. The first lane was loaded with 10 m g
of COS cell lysate containing transfected
hPar-6 as a size control.
mammalian atypical PKC, we first examined the ability of
GST–hPar-6 to bind to human PKCz translated in vitro.
GST–hPar-6 efficiently bound PKCz whereas the GST
control showed little binding (Figure 3a). In contrast,
GST–hPar-6 did not bind a conventional PKC, PKCa
(Figure 3a) [33]. Furthermore, GST–hPar-6 bound purified
recombinant human PKCz , but not a novel PKC, PKCd
(Figure 3b) [33]. These data indicate that hPar-6 binds
directly and specifically to PKCz .
To define the region in hPar-6 responsible for its interac-
tion with PKCz , we generated various deletion mutants of
hPar-6 (Figure 3c). Constructs encoding Myc-tagged ver-
sions of these mutants were co-transfected with a construct
encoding PKCz into COS cells and immunoprecipitation
was carried out using the anti-Myc monoclonal antibody,
9E10. PKCz co-immunoprecipitated with hPar-6, indicat-
ing that these two proteins interact in vivo (Figure 3d).
Deletion of the CRIB motif did not affect the binding of
PKCz (Figure 3d) whereas it abolished the interaction of
hPar-6 with Rac1/Cdc42 (Figure 2a,e), suggesting that
PKCz and Rac1/Cdc42 interact with hPar-6 at different
sites. The amino-terminal region of hPar-6 was necessary
and sufficient for interaction with PKCz , and the PDZ plus
CRIB domains or the carboxyl terminus displayed no
detectable binding (Figure 3e,f). Deletion of both CRIB
and PDZ domains from hPar-6, however, caused a reduc-
tion in PKCz binding (Figure 3e,f), possibly because acces-
sibility of the amino-terminal domain is compromised.
Alternatively, elements in the CRIB and PDZ domains
may contribute to PKCz binding. Similar co-immunopre-
cipitation experiments demonstrated that overexpressed
hPar-6 or hPar-N  (see Fig. 3c) interacted with endogenous
PKCz (Figure 3d,f). hPar-6 also interacted with catalytically
inactive (kinase-dead) PKCz (Figure 3e). Furthermore, we
showed that endogenous Par-6 and PKCz co-immunopre-
cipitated from three different cell lines including murine
fibroblasts (NIH-3T3), rat intestinal epithelial cells
(IEC18), and human colon carcinoma cells (SW480)
(Figure 3g). Taken together, these data indicate that Par-6
associates with PKCz in vivo and that this association is
mediated by the amino-terminal region of hPar-6 and is
independent of PKCz kinase activity. T he physiological sig-
nificance of this association is suggested by the formation of
a complex between the endogenous proteins (Figure 3g).
Because hPar-6 interacts with both Rac1/Cdc42 and PKC z ,
we investigated whether Rac1 or Cdc42 and PKC z form
ternary complexes with hPar-6 by co-transfection in COS
cells. Immunoprecipitation of hemagglutinin (HA)-tagged
Rac1(Q61L) or Cdc42(Q61L) recovered considerably
more PKCz in the presence of overexpressed hPar-6 than
in its absence (Figure 4a). Rac1(T17N) or Cdc42(T17N)
did not precipitate significant amounts of PKC z even
when hPar-6 was overexpressed. Similarly, endogenous
PKCz co-immunoprecipitated with activated Rac1 and
Cdc42, but to a much lesser extent with dominant-nega-
tive versions of these proteins (Figure 4b). In addition,
when the CRIB deletion mutant of hPar-6 (hPar- D CRIB)
was overexpressed, the amount of PKC z co-precipitated
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Figure 4
hPar-6 physically links Rac1/Cdc42 to PKCz . (a) hPar-6-dependent
association between Rac1/Cdc42 and PKCz . The expression
construct indicated above each lane was co-transfected into COS
cells with a construct expressing PKCz . Cell lysates were analyzed by
immunoprecipitation (IP) with F-7 anti-HA followed by western blotting
(WB) with anti-PKCz . (b) Association of endogenous PKCz with
Rac1/Cdc42. COS cell lysates containing the proteins indicated
above each lane were analyzed by immunoprecipitation with F-7 anti-
HA followed by western blotting with anti-PKCz . (c) CRIB-dependent
activation of PKCz by hPar-6. Expression constructs encoding Myc-
tagged vector, hPar-6 or hPar-D CRIB were co-transfected into COS
cells with the construct expressing PKCz . Cell lysates were
immunoprecipitated with anti-PKCz and PKCz kinase activity assayed
(see Materials and methods). The upper panel shows the quantification
of the radiolabel incorporated into myelin basic protein (MBP) (relative
to the vector control). The middle panel is a representative
autoradiogram showing phosphorylated MBP (p-MBP). The lower
panel displays the expression of PKCz in the lysates. (d) Effect of
Rac1/Cdc42 on PKCz activation by hPar-6. Assays were carried out
and are represented as in (c). The error bars in (c) and (d) represent
standard deviation of two to three independent experiments carried out
in single set. In (b,c), the order of the bars in the upper panel
corresponds to the order of the lanes in the lower panels.
with Rac1 or Cdc42 did not increase (Figure 4a). These
results strongly suggest that hPar-6 can bridge activated
Rac1/Cdc42 and PKC z to form a stable complex in vivo.
Overexpression of hPar-6 stimulates PKCz kinase activity
To determine whether complex formation with Rac1 and
hPar-6 affects PKCz kinase activity, immune-complex
kinase assays were carried out using myelin basic protein
(MBP) as a substrate. Overexpression of hPar-6 in COS
cells stimulated PKCz kinase activity about threefold,
whereas deletion of the CRIB motif abrogated this stimu-
lation (Figure 4c). These results indicate that hPar-6 not
only interacts with PKCz, but also stimulates its catalytic
activity. They also suggest that the interaction of hPar-6
with Rac1/Cdc42 is required for this stimulation. Consis-
tent with a role for Rac1/Cdc42 in hPar-6-mediated PKCz
activation, co-expression of Rac1(T17N) or Cdc42(T17N)
blocked this effect (Figure 4d). Conversely, Rac1(Q61L)
and Cdc42(Q61L) further potentiated PKCz activation by
hPar-6 but the increase was modest (Figure 4d), suggest-
ing that endogenous Rac and Cdc42 may be sufficient for
activation of PKCz by overexpressed hPar-6. 
Par-6 potentiates cell transformation by Rac1 
We and others have shown previously that constitutive acti-
vation of Rac1 and Cdc42 leads to cell transformation and
that the pathway(s) mediated by Rac1/Cdc42 are critical for
Ras transformation [8–11,13]. The downstream pathway(s)
responsible for the transforming activity of Rac/Cdc42
remains elusive, however. Although many effectors of Rac1
and Cdc42 have been isolated [2], none of them has been
shown to directly mediate Rac1- or Cdc42-induced trans-
formation. The demonstrated roles of PKC z in mitogenic
[25] and survival signaling [28,34] and the biochemical link
that we had found between Rac1/Cdc42, hPar-6 and PKC z
led us to test the possibility that Rac1/Cdc42 might elicit
cell transformation via hPar-6 and PKC z .
We first examined interaction of hPar-6 with a panel of
Rac1 effector domain mutants that had been characterized
with respect to transformation in cooperation with activated
Raf [35]. Rac1(G12V;T35S) with no transforming ability
showed no binding to hPar-6, whereas Rac1(N26D;Q61L)
and Rac1(N43D;Q61L) with reduced transforming poten-
tial had reduced affinity toward hPar-6 (data not shown).
Thus, the strength of Rac1–hPar-6 association correlates
with the potency of Rac1-induced transformation. 
To provide direct evidence for a role of hPar-6 and PKC z
in Rac1/Cdc42 transformation, focus assays were carried
out in NIH-3T3 cells. Consistent with previous observa-
tions [8,10], activated Rac1 alone weakly transformed the
cells. hPar-6 or hPar- D CRIB alone showed even weaker, if
any, transforming capability. In marked contrast, co-trans-
fection of hPar-6 with Rac1(G12V) potentiated focus for-
mation by about tenfold, whereas deletion of the hPar-6
CRIB motif completely abolished this effect (Figure 5a).
To rule out the possibility that the increase in focus forma-
tion results merely from an increase in expression of Rac1
and/or hPar-6, we examined transiently transfected lysates
by western blotting. hPar-6 and hPar- D CRIB were
expressed at comparable levels, whereas the level of
Rac1(G12V) was actually lower in cells co-expressing
hPar-6 (Figure 5b), despite the more potent transformation
effect observed. This result suggests that hPar-6 causes
the transformation effect directly by interacting with Rac1.
A number of independent foci from cells transfected with
Rac1(G12V) plus hPar-6 were examined for expression of
these proteins. All eight foci analyzed contained both
Myc–Rac1(G12V) and Myc–hPar-6 (Figure 5c), supporting
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Figure 5
hPar-6 potentiates transformation by Rac1.
(a) Results of focus assays in NIH-3T3 cells,
showing the CRIB-dependent potentiation of
Rac1 transformation by hPar-6. Data are from at
least four independent experiments performed
in duplicate. The amount of DNA used in each
transfection was 1 m g for each plasmid.
(b) Western blotting with 9E10 anti-Myc
showing expression levels of Myc-tagged hPar-
6, hPar-D CRIB, hPar-2HP and Rac1(G12V) in
transfected NIH-3T3 cells in a typical focus
assay. Cells were transfected with constructs
encoding the proteins indicated above each
lane. Lanes 4–8 (designated +Rac1V12) were
also co-transfected with Myc–Rac1(G12V).
KD-z , kinase-dead PKCz ; WT-z , wild-type
PKCz . (c) Western blotting with 9E10 anti-Myc
showing expression of both Myc-tagged hPar-6
and Rac1V12 in independent foci isolated from
dishes transfected with plasmids encoding
Myc–hPar-6 and Rac1(G12V). Lanes 1–8
represent lysates from different foci, and lane 0
represents a lysate from cells transfected with
vector alone.
the conclusion that the cell transformation observed is
promoted by Rac1 and hPar-6 acting in concert. More-
over, the morphology of foci induced by Rac1(G12V) plus
hPar-6 appears very similar to that induced by
Rac1(G12V) alone, except that the Rac1 foci are usually
smaller (see below). On the other hand, we did not
observe any effect of PAK1 (a Rac/Cdc42 effector) or
POR1 (a Rac-specific effector) on Rac1(G12V) transfor-
mation [2] (data not shown), suggesting that the effect of
hPar-6 on Rac1 transformation is specific. 
PKCz has an essential role in cell transformation by Par-6
To further elucidate the downstream elements in the
Rac1/hPar-6 pathway, we investigated the role of PKCz in
mediating transformation by Rac1 and hPar-6. We made
use of a well-characterized, catalytically inactive (kinase-
dead), dominant-negative mutant of PKCz (KD-z )
[25,36,37] to inhibit endogenous PKCz activation. Co-
expression of KD-z strongly reduced the transforming
potential of Rac1 plus hPar-6, whereas co-expression of
wild-type PKCz (WT-z ) further enhanced transformation
by Rac1 plus hPar-6 (Figure 6). WT-z only slightly
increased transformation by Rac1 or hPar-6 alone
(Figure 6). Introduction of KD-z and WT-z did not increase
the expression level of Rac1(G12V) or hPar-6 (Figure 5b).
These data strongly suggest that PKCz kinase activity is
required for Rac1 and hPar-6 to transform fibroblasts. Con-
sistent with a role for PKCz in mediating hPar-6 transforma-
tion, hPar-2HP and hPar-D N (see Figure 3c), which
interacted at most very weakly with PKCz , did not potenti-
ate Rac1 focus formation (Figures 3c,6 and data not shown).
Moreover, hPar-C and hPar-(CRIB+PDZ) (Figure 3c),
which did not interact with PKCz , also did not promote cell
transformation (data not shown).
To examine whether focus formation induced by Rac1,
hPar-6 and PKCz correlates with other transformation
phenotypes such as anchorage-independent growth, we
assayed cells from transformed foci for growth in soft agar.
Cells grown from four independent foci induced by either
Rac1(G12V) and hPar-6, or Rac1(G12V) and hPar-6 plus
PKCz all formed colonies in soft agar, whereas cells trans-
fected by the vector only did not (see Supplementary
material). The growth efficiency in soft agar ranges from 
1 to 7%. This result suggests that activation of the
Rac1/hPar-6/PKCz pathway can also confer other transfor-
mation phenotypes on NIH-3T3 cells. 
The Rac1/hPar-6/PKCz pathway is distinct from the
RafCAAX-mediated pathway
It has been demonstrated by us and others that Rac1 and
RafCAAX, a membrane-targeted, constitutively active Raf
kinase, may control two distinct pathways downstream of
Ras that cooperate to promote cell transformation [5,8,10].
To assess whether hPar-6 and PKCz comprise the pathway
downstream of Rac1 that synergizes with RafCAAX, we
tested the effect of PKCz on RafCAAX-induced transfor-
mation. The synergy between Rac1 and RafCAAX was
inhibited by KD-z and enhanced by WT-z (Figure 7a).
Moreover, WT-z modestly stimulated RafCAAX transfor-
mation. On the other hand, KD-z did not have a significant
effect on focus formation induced by RafCAAX alone
(Figure 7a) or by RhoA(G14V) (data not shown). In addi-
tion, the morphology of transformed foci induced by Rac1
and hPar-6, or by Rac1 and hPar-6 plus PKCz, is similar to
that induced by Rac1 alone, but quite different from that
induced by RafCAAX (Figure 7b): foci induced by the
Rac1/hPar-6/PKCz pathway are dense, and contain rounded
cells that pile up, including many multinucleated cells,
whereas foci induced by RafCAAX are less dense and
contain spindle-shaped cells that do not pile up (Figure 7b).
Moreover, many foci induced by Rac1 plus RafCAAX look
similar to those induced by the Rac1/hPar-6/PKCz pathway
(Figure 7b). These observations indicate that the inhibitory
effect of KD-z is specific to the Rac1 pathway and support
the idea that hPar-6 and PKCz mediate a signaling pathway
downstream of Rac1 that is distinct from the RafCAAX-
mediated pathway. Consistent with the proposal that Rac1
mediates a growth control pathway downstream of Ras
[8,10], KD-z also significantly inhibited transformation
induced by oncogenic Ras (Figure 7a). In agreement with
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Figure 6
PKCz mediates transformation by Rac1/hPar-6. Results of focus
assays showing the effect of PKCz on cell transformation induced by
Rac1 and hPar-6. Data are from two to four independent experiments
performed in duplicate. The amount of DNA in each transfection was:
1 m g for Rac1V12, hPar-6 or hPar-2HP; 2 m g for KD-z or WT-z . 
these observations, it was recently reported that PKCz can
act in a pathway downstream of Ras and Rac1 that leads to
disassembly of actin stress fibers, a phenotype characteristic
of transformed cells [38].
hPar-6 and PKCz mediate cell transformation by Cdc42
As Cdc42 has a role in cell transformation [5] and can also
undergo GTP-dependent interaction with hPar-6, we
carried out similar focus assays to determine whether hPar-6
and PKCz mediate transformation by Cdc42. We found that
overexpression of hPar-6 and PKCz increased focus forma-
tion by Cdc42(Q61L) (Figure 8), suggesting that signaling
from hPar-6 to PKCz also promotes transformation by
Cdc42. This effect was, however, much weaker than in the
case of Rac1, and Cdc42 alone did not induce any foci
(Figure 8). In addition, the transformed foci induced by
Cdc42 and hPar-6 appeared flatter than those induced by
Cdc42 and hPar-6 plus PKCz (see Supplementary material),
and the foci contained fewer multinucleated cells than
those induced by the Rac1/hPar-6/ PKC z pathway (compare
Figure 7b with Figure S4 in Supplementary material).
Discussion
It has become evident in the past several years that Rac1
and Cdc42 have important roles in cell growth control
and that their signaling contributes to cell transformation
by oncogenic Ras. The biochemical mechanisms under-
lying this effect remain obscure, however. Many direct
targets of Rac1 and Cdc42 have been identified [14], but
none has been shown to have a direct role in cell transfor-
mation by Rac1 and Cdc42. We have identified hPar-6 as
a novel effector of Rac1 and Cdc42 that promotes PKC z -
dependent transformation by both GTPases. Although it
has been suggested that PAK1 may also contribute to
transformation by Rac1 in Rat1 fibroblasts [39], we found
that PAK1 does not enhance transformation by activated
Raf or activated Rac1 in NIH-3T3 cells (data not shown),
and studies using effector domain mutants indicated that
interaction of PAK1 with Rac1 does not correlate with
cell-cycle progression or transformation [2,5]. Thus, to
our knowledge hPar-6 is the first effector shown to
directly mediate transformation by Rac1 and Cdc42. The
identification of PKC z as a downstream effector of hPar-6
represents the first elucidation of a signaling pathway
linking Rac1/Cdc42 to cell transformation (Figure 9). 
The mechanism by which hPar-6 regulates the kinase
activity of PKCz is currently under investigation. Subcel-
lular targeting by interaction with specific proteins pro-
vides an attractive mechanism for PKC isozyme-specific
regulation [40]. It is possible that hPar-6 and PKCz are
translocated by Rac1 or Cdc42 to the membrane, where
PKC z could interact with an activator. One candidate
activator is the phosphatidylinositol 3-kinase (PI3-
kinase) target PDK1, as PDK1 and PKC z associate
in vivo via their catalytic domains, and both PI3-kinase
and PDK1 stimulate PKC z activity [41–43]. Consistent
with this model (Figure 9), it has been demonstrated that
PI3-kinase can act as a link between Ras and Rac in
transformation and that membrane-targeted PKCz is con-
stitutively active [43–45]. The observation that hPar-6
alone exhibits little, if any, transforming activity is also
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Figure 7
The hPar-6/PKCz pathway is distinct from the RafCAAX-mediated
pathway. (a) Results of focus assays showing the effect of PKCz on
the transforming synergy between Rac1 and RafCAAX and on
transformation induced by Ras. The amount of DNA used in each
transfection was: 100 ng for Rac1(G12V) or RafCAAX; 2 m g for KD-z
or WT-z ; 10 ng for Ras(G12V). RafCAAX-H designates the higher
amount of DNA (1 m g) that was used to obtain a higher number of foci.
Data are from two independent experiments performed in duplicate.
(b) Morphologies of different foci transformed by the protein(s)
indicated in each panel.
consistent with the membrane-targeting model. It should
also be noted that although overexpression of hPar-6 alone
(i.e., in the absence of Rac1[G12V]) is sufficient to acti-
vate PKCz kinase activity (Figure 4c), overexpression of
hPar-6 and PKCz only marginally promotes focus forma-
tion (Figure 6), suggesting that activated Rac1 is necessary
to target PKCz to substrates involved in transformation.
However, we cannot rule out the possibility that Rac1
activates some other pathway that is also necessary for
transformation. In addition to being activated by hPar-6,
PKCz might in turn phosphorylate hPar-6 (Figure 9). In
this regard, it should be noted that there is a putative
PKCz -phosphorylation site [46] in mammalian Par-6.
The mechanism underlying transformation by hPar-6 and
PKCz is not yet clear. Stimulation of cell proliferation and
inhibition of apoptosis are, however, important character-
istics of cell transformation [47]. In this regard, it has been
shown that Rac1 and Cdc42 induce cyclin D1 transcrip-
tion and accumulation, phosphorylation and inactivation
of the tumor suppressor protein Rb, and activation of the
transcription factor E2F [5,48]. Inactivation of Rb may be
necessary for Rac1/Cdc42 stimulation of cell proliferation,
and it is possible that hPar-6 and PKCz have a role in this
pathway. In addition, Ras, Rac1, Cdc42 and PKCz are all
able to activate the transcription factor NF-k B [2,5,27,37].
NF-k B activation is associated with mitogenesis, anti-
apoptotic activity and cell transformation [7,49,50]. Thus,
the hPar-6–PKCz pathway might mediate NF-k B activa-
tion, and thereby contribute to cell transformation by Rac1
and Ras. Another possibility is that the hPar-6–PKCz
pathway may mediate growth control by Rac1/Cdc42 by
inducing downregulation of the pro-apoptotic protein
Par-4 (prostate apoptosis response-4; unrelated to the
C. elegans Par gene product) [28]. Par-4 interacts with
PKCz and overexpression of PKCz downregulates Par-4,
an event that appears important for Ras transformation
and tumor progression [28]. Thus, cyclin D1, Rb, E2F,
NF-k B and Par-4 all warrant further investigation as possi-
ble downstream targets of the hPar-6–PKCz pathway.
Polarity is a fundamental feature of all eukaryotic cells
[51]. Rac, Cdc42, Par-6 and atypical PKCs appear to be
conserved in diverse metazoans, including Drosophila,
C. elegans, Xenopus, mouse and humans [22,32,52]. The
CRIB motif of Par-6 is also conserved, suggesting that it
interacts with Rac and/or Cdc42 in these different
species. In C. elegans, inhibition of Cdc42 function by
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Figure 8
hPar-6 promotes transformation by Cdc42. Results of focus assays
showing CRIB- and PKCz -dependent transformation by hPar-6
together with Cdc42(Q61L). The amount of DNA used in each
transfection was: 1 m g for vector, Cdc42(Q61L), hPar-6, hPar2HP or
hPar- D CRIB; 2 m g for KD-z or WT-z . Data are from two independent
experiments performed in duplicate.
Figure 9
Schematic of the model depicting two separate pathways downstream
of Ras that lead to cell polarity and growth control, and which can
contribute to cell transformation. One comprises Rac/Cdc42, hPar-6
and PKCz , and the other is mediated by Raf, MEK and MAP kinase.
RNA-mediated gene interference (RNAi) [53] produced
defects in cell polarity similar to those observed in par and
pkc-3 mutants (A. Kay and C.P. Hunter, personal commu-
nication; A. Romano and M. Glotzer, personal communica-
tion), while in mammalian cells, Par-6 is localized to tight
junctions, together with atypical PKC and ASIP, the mam-
malian homolog of Par-3 (T. Yamanaka and S. Ohno, per-
sonal communication). Moreover in C. elegans, Par-6
interacts with Par-3, and in Drosophila the Par-3 homolog
has an important role in the asymmetric cleavage of
epithelial cells and neuroblasts [21,54,55]. Taken together,
these observations suggest that Rac or Cdc42, Par-6, atypi-
cal PKC, and perhaps Par-3, constitute a conserved
pathway that regulates cell polarity. As we have shown that
hPar-6 and PKC z mediate cell transformation by Rac1 and
Cdc42, there may be a link between cell-polarity signaling
and growth control: aberrant cell-polarity signaling could
lead to oncogenic transformation (Figure 9). In the light of
the important roles of Rac1/Cdc42 in Ras-induced trans-
formation, hPar-6 and PKC z could represent potential
targets for anti-cancer therapeutics.
Conclusions
Our findings indicate that hPar-6, the human homolog of a
C. elegans cell-polarity determinant, is a novel effector of
Rac1 and Cdc42. hPar-6 provides a link between Rac or
Cdc42 and PKCz in a pathway that is involved in cell trans-
formation. To our knowledge, hPar-6 is the first effector
shown to directly mediate Rac1- or Cdc42-induced trans-
formation, and the identification of PKC z as a downstream
element in this pathway represents the first elucidation of a
molecular mechanism by which Rac and Cdc42 can control
cell growth. This pathway seems to be distinct from the
Raf-mediated pathway, and both pathways are essential for
cell transformation by Ras. These findings suggest a link
between cell-polarity signaling and cell transformation.
Materials and methods
Northern blot analysis
A poly(A)+ multiple-tissue Northern blot (Clontech) was probed with
2HP-4 cDNA labeled with [32P]dCTP using the Megaprime DNA
Labelling System (Amersham). 
Transient transfections
All transfections were carried out in COS cells using either Superfect
(Qiagen) according to the protocol provided by the manufacturer, or
electroporation at 250 V and 125 m F. Cell lysates were prepared 48 h
post-transfection using mammalian cell lysis buffer containing 40 mM
HEPES pH 7.4, 100 mM NaCl, 1% TritonX-100, 5 mM MgCl2, 1 mM
EDTA and protease and phosphatase inhibitors.
SDS–PAGE and western blot analyses
All the SDS–PAGE and western blot analyses were carried out as pre-
viously described [9].
In vitro interaction assays (GST fusion affinity precipitation)
GST fusions (10–20 m g) were incubated for 2 h at 4°C with cell lysates
containing proteins of interest, then washed three times with bacterial
lysis buffer containing 40 mM Tris pH 8.0, 100 mM NaCl, 1% Triton
X-100, 10 mM MgCl2, 1 mM EDTA and protease inhibitors. When in vitro
translated products were used, the proteins were generated using a
coupled transcription and translation (TNT) kit (Promega) and labeled with
[35S]methionine; the precipitated proteins were visualized by autoradiog-
raphy. When purified recombinant proteins were used, 2–3 m g of each
recombinant protein was mixed with 20 m g of BSA in 200 m l bacterial lysis
buffer. Proteins precipitated from lysates of transiently transfected cells or
from purified preparations were visualized by western blot analysis. 
In vivo interaction assays (co-immunoprecipitation)
Constructs encoding proteins of interest were transfected into COS
cells. Cell lysates containing 200–500 m g of total proteins were incu-
bated at 4°C for 2 h with either 9E10 anti-Myc monoclonal antibody to
precipitate Myc-tagged hPar-6-derived proteins, F-7 anti-HA mono-
clonal antibody (Santa Cruz Biotechnology) to precipitate HA-tagged
Rac1/Cdc42/RhoA mutants, or anti-PKCz polyclonal antibody (Santa
Cruz Biotechnology) to precipitate endogenous and overexpressed
PKCz . The immunoprecipitates were washed three times with mam-
malian cell lysis buffer and the co-precipitated proteins were detected
by western blot analysis with specific antibodies.
Immune-complex PKCz kinase assays
Total protein from COS cell lysates (500 m g in each assay) overex-
pressing PKCz and proteins of interest were immunoprecipitated with
1–2 m g anti-PKCz polyclonal antibody or 1 m g anti-V5 epitope tag mon-
oclonal antibody (Invitrogen). The PKCz construct contained the V5
epitope tag at the carboxyl terminus of PKCz . The immunoprecipitates
were then incubated with MBP and [g -32P]ATP [56]. The phosphory-
lated MBP was visualized by autoradiography and quantified. 
Focus assays 
The assays were carried out in NIH-3T3 cells essentially as described
previously [8]. For the experiment shown in Figure 5b, transfection was
done in triplicate. Two were maintained for focus formation, the other
one was used to make cell lysate 2 days post-transfection for western
blot analysis.
Soft agar assays
Individual transformed foci were isolated and cultured. Cells from these
foci were then assayed for growth in soft agar essentially as described
previously [8].
Supplementary material
Supplementary material including a description of the cloning and sub-
cloning of hPar-6 cDNA and additional figures is available at
http://current-biology.com/supmat/supmatin.htm.
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